CDK4 and Hyperinsulinemia: This dependency on cyclin D1-driven checkpoint control highlights the cyclin D1-CDK4/6 axes as an interesting therapeutic target [43] that warrants further preclinical and clinical investigation in ER-positive BC patients with hyperinsulinemia.